Cross-Sector entity
Of the tracked stories, 3 of 3 also mention AstraZeneca, the most common co-covered peer. acquisition accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each. Opdivo appears in 3 tracked Cross-Sector stories from August 2, 2026.
3 verified stories tracked
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention AstraZeneca, the most common co-covered peer. acquisition accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each. Opdivo appears in 3 tracked Cross-Sector stories from August 2, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Opdivo. Shared-story counts are live from our verified record — not editorial picks.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
